Generated by AI
Grace Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Grace Therapeutics, Inc. currently centers on drug candidates designed to address serious neurological and pain-related conditions, including GTx-104 for aneurysmal subarachnoid hemorrhage, GTx-102 for Ataxia-Telangiectasia, and GTx-101 for postherpetic neuralgia. The company works with proprietary drug-delivery technologies aimed at improving how established molecules are formulated and administered in clinical settings. Its portfolio is positioned at the intersection of specialty pharmaceuticals and rare-disease treatment, supporting hospitals, physicians, and patients managing complex unmet medical needs. Grace Therapeutics, Inc. is headquartered in Princeton, New Jersey.
Website103 Carnegie Center
Princeton, NJ, 08540
United States
The latest articles about GRCE.
Summary of Jul 13's posts. Generated by AI.
Summary of Jul 13's posts. Generated by AI.
No summary yet.
No summary yet.
Investors talking about GRCE also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.